• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Cellebrite Stock Earnings Beat As US Move And AI Push Take Shape

    Simply Wall St·11/14/2026 00:39:47
    Listen to the news
    • Cellebrite DI reported Q3 2026 results with revenue of US$149.02 million and net income of US$26.66 million, and outlined plans to redomicile in the U.S. while expanding its Genesis AI platform and on premise offerings.
    • An interesting angle for investors is how Cellebrite DI’s stronger international demand and U.S. federal momentum intersect with its AI driven Genesis platform as the business shifts further toward subscription and investigative intelligence workflows.
    • Next, the focus will be on how Cellebrite DI’s U.S. redomiciling plan could reshape the existing investment narrative around its AI pivot.

    Scan how Cellebrite DI’s AI and digital intelligence story compares with other potential breakouts by lining it up against a curated set of 42 profitable AI stocks that aren't just burning cash in the same space.

    Cellebrite DI Investment Narrative Recap

    To own Cellebrite DI, you need to buy into the idea that its digital intelligence platform and AI tools like Genesis can keep driving subscription ARR, even as procurement friction and prior guidance cuts linger in the background. The analyst consensus narrative on Simply Wall St leans on that shift, and the latest quarter, with US$149.02 million in revenue and US$26.66 million in net income, supports an operating story that is still functioning and not resetting again.

    The more immediate swing factor remains whether cloud and AI contracts close fast enough to keep ARR in line with already reduced targets. The biggest risk continues to be any further disappointment on ARR or revenue versus guidance, given past cuts, legal investigations and the recent CEO change. Q3 did not remove that risk, but it did not obviously worsen it either.

    Among recent developments, the appointment of Rogerio Rizzi as Executive Vice President for Corporate Strategy and Development feels most relevant to the Q3 story. Cellebrite DI is clearly leaning harder into AI driven workflows and a broader public safety and intelligence footprint, and Rizzi’s background at Okta, SAP and Hewlett Packard Enterprise ties directly into that push.

    For you as an investor, the question is whether this hire improves execution on the catalysts already flagged, such as converting Genesis, Guardian and defense offerings into consistent ARR while dealing with longer sales cycles and regulatory friction. If management can align product, pricing and go to market around that, the raised 2026 EBITDA guidance and high gross margins have more support, rather than relying only on cost control.

    Cellebrite DI’s current earnings are US$58.2 million, with analyst consensus pointing to US$122.0 million in earnings and US$787.4 million in revenue by 2029. This implies forecast revenue growth of 15.3% per year and an earnings increase of about US$63.8 million from today.

    Discover how Cellebrite DI's fair value indicates a 33% potential upside to its current price, which could narrow quickly as sentiment and funding catch up.

    NasdaqGS:CLBT 1-Year Stock Price Chart
    NasdaqGS:CLBT 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate view focuses on regulatory friction. The most cautious analysts worry that longer cloud and AI deal cycles could eat into Cellebrite DI’s AI payoff. Before this Q3 update, the lowest group still penciled in about US$813.7 million of revenue and US$133.8 million of earnings by 2029. That is actually more optimistic on long term growth than the baseline, yet paired with a lower US$12.5 price target. You can read that as a story in which execution risk and compliance costs weigh heavily on valuation. Use that as a reminder that equally informed analysts can look at the same pre news data and reach very different conclusions, so it is worth exploring several narratives before deciding how this Q3 news might shift your own view.

    Explore 3 other Cellebrite DI fair value estimates, including one that suggests it could be worth just $12.50.

    The Verdict Is Yours

    Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

    Looking For More Ideas Beyond Cellebrite DI?

    If this Cellebrite DI update has sharpened your thinking about AI and digital intelligence, it can be useful to pressure test that thesis against other opportunities on the Simply Wall St Screener. Frame what you like about this stock, then see which other businesses share those traits on quality, balance sheet strength or income potential.

    • For investors who prioritize financial resilience and cleaner balance sheets, compare Cellebrite DI with a list of solid balance sheet and fundamentals (24 results) that can handle tougher conditions without relying heavily on new funding.
    • If you are hunting for mispriced quality, line up your Cellebrite DI thesis against a 32 high quality undervalued stocks that combines fundamentals with prices that analysts and models see as out of sync.
    • Anyone building a portfolio around reliable income streams can round out this kind of growth story by reviewing a 6 dividend fortresses that aims to pair higher yields with underlying business stability.